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A B S T R A C T
Five carbapenem-resistant Acinetobacter baumannii
isolates, collected from the United Arab Emirates
in 2006, were investigated to identify the mech-
anism(s) responsible for carbapenem resistance.
Genotyping was performed by pulsed-field gel
electrophoresis, and the location of the blaOXA-23
gene was determined by using the endonuclease
I CeuI technique and mating-out assays. The four
isolates in which the blaOXA-23 gene was located
on the chromosome within a Tn2006 composite
transposon were clonally related. The single non-
clonally related isolate harboured the blaOXA-23
gene on a 70-kb transferable plasmid. This study
reports on the dissemination of OXA-23-produc-
ing A. baumannii isolates in the Middle East.
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Carbapenem resistance in Acinetobacter bauman-
nii is increasingly being observed worldwide.
Several studies have reported metallo-b-lacta-
mases (MBLs) [1], but the most common mech-
anism is related to carbapenem-hydrolyzing
class D b-lactamases (CHDLs) [2]. Three main
acquired CHDL gene clusters have been de-
scribed in A. baumannii, containing blaOXA-23-like,
blaOXA-40-like or blaOXA-58-like genes. The blaOXA-23
gene is either plasmid-borne or chromosome-
borne [3,4], and A. radioresistens was recently
identified as the progenitor of blaOXA-23-like
genes [5].
From July 2006 to November 2006, five carba-
penem-resistant A. baumannii isolates causing
fatal infections in five patients were collected
from the adult intensive-care unit of Sheikh
Khalifa Medical City. Whereas two isolates were
considered to be colonizing agents, three were
involved in infections, two of which caused
septicaemia. The age of the patients ranged from
30 to 60 years, and all of them had been treated
with colistin and tobramycin, except patient 3,
who was treated with colistin and tigecycline
(Table 1).
The isolates were identified after 16S rRNA
gene sequencing [6]. MICs of imipenem and
meropenem were determined using antibiotic
disks from Sanofi Diagnostics Pasteur (Marne-
La-Coquette, France) [7] and were found to be
32 mg ⁄L (Table 2). The isolates were resistant to
almost all antibiotics, including aminoglycosides,
fluoroquinolones and b-lactams (Table 2).
The production of MBLs was evaluated using
the MBL Etest, combining imipenem and EDTA as
recommended by the manufacturer (AB Biodisk,
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Solna, Sweden), but all isolates gave negative
results. However, PCR experiments followed by
sequence analysis led to the identification of
blaOXA-23, in addition to the natural blaOXA-69
b-lactamase gene, in all isolates. The insertion
sequence ISAba1 was detected upstream of the
blaOXA-23 gene in all isolates; however, no colin-
earity was found between ISAba1 and blaOXA-69,
thus making any ISAba1-mediated overexpression
of this naturally occurring carbapenemase gene
unlikely [8].
Genotypic comparison was performed by
pulsed-field gel electrophoresis according to the
manufacturer’s recommendations (Bio-Rad, Mar-
nes-la-Coquette, France). Whole cell DNA of the
A. baumannii isolates was digested with ApaI
overnight at 37C (New England Biolabs, St
Quentin-en-Yvelines, France). Electrophoresis
was performed with a CHEF DRII apparatus
(Bio-Rad) through a 1% agarose gel in 0.5· Tris–
borate–EDTA buffer. Migration conditions were
as follows: temperature, 14C; voltage, 6 V ⁄ cm;
and switch angle with one linear switch ramp of
3–8 s for 10.5 h, and then 12–20 s for 10.5 h. The
analysis showed that four of the five carbapenem-
resistant isolates belonged to a single clone
according to the Tenover criteria. This result is
in accordance with the results of blaampC gene
sequencing as previously described [9], indicating
perfect identity among isolates 1, 2, 4 and 5,
whereas a 10-bp divergence was found in iso-
late 3 (data not shown). Interestingly, all four
patients infected with the same clonal strain
had received the same antimicrobial regimen,
and identical MICs were determined for their
isolates (Table 2). Thus, the dissemination of an
OXA-23-producing clone within this hospital was
assessed, but, interestingly, another OXA-23-pro-
ducing strain had also caused infection of a
patient.
To search for a chromosomal location of the
b-lactamase gene, the endonuclease I CeuI (New
England Biolabs) was used, which digests a 26-
bp sequence in the rrn genes for the 23S rRNA
[10], and the fragments were separated by
pulsed-field gel electrophoresis. DNA–DNA
hybridization of the fragments was then per-
formed, using the Southern technique as previ-







(day ⁄month ⁄ year)
Date of
hospitalization







infection Underlying disease Outcome
1 Resistant 24 ⁄ 7 ⁄ 2006 2 ⁄ 6 ⁄ 2006 Blood Colonized Colistin and tobramycin Duodenal ulcer,
peritonitis, septic shock
Died
2 Resistant 13 ⁄ 8 ⁄ 2006 14 ⁄ 7 ⁄ 2006 Blood Colonized Colistin and tobramycin Pneumonia Died
3 Resistant 2 ⁄ 10 ⁄ 2006 1 ⁄ 10 ⁄ 2006 Blood Infected Colistin and tigecycline Pancreatitis Died
4 Resistant 6 ⁄ 10 ⁄ 2006 4 ⁄ 4 ⁄ 2006 Blood Infected Colistin and tobramycin Peritonitis Died
5 Resistant 3 ⁄ 11 ⁄ 2006 15 ⁄ 10 ⁄ 2006 CSF Infected Colistin and tobramycin Polytrauma Died
CSF, cerebrospinal fluid.
Table 2. MICs of b-lactams for the five OXA-23-positive Acinetobacter baumannii isolates, Escherichia coli TOP10 (pAS1),
reference strain E. coli TOP10, A. baumannii transconjugant expressing OXA-23, and reference strain A. baumannii BM 4547
b-Lactam(s)
A. baumannii











Amoxycillin >512 >512 >512 2 >512 16
Amoxycllin + CLA 512 >512 16 2 64 16
Ticarcillin >512 >512 >512 1 >512 8
Ticarcillin + CLA >512 >512 256 1 >512 8
Piperacillin 256 256 4 1 >512 4
Piperacillin + TZB 256 256 4 1 >512 4
Cephalotin 256 256 1 4 256 256
Cefuroxime 256 256 1 1 16 16
Ceftazidime 256 256 <0.06 <0.06 4 4
Cefotaxime 256 256 <0.06 <0.06 32 32
Cefepime 256 256 <0.06 <0.06 256 32
Cefpirome 256 256 <0.06 <0.06 >512 64
Aztreonam 128 >512 <0.06 0.06 128 128
Imipenem 32 32 0.25 <0.06 16 0.25
Meropenem 32 32 0.32 <0.06 >32 1
CLA, clavulanic acid (4 lg ⁄mL); TZB, tazobactam (4 lg ⁄mL); E. coli TOP10 (pAS1) expressing the chromosomally located blaOXA-23 gene from plasmid pBK-CMV cloning
vector; A. baumannii BM 4547 blaOXA-23 expressing the blaOXA-23 plasmid-borne gene.
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ously described [11], with two probes: an 884-bp
PCR-generated probe specific for the 16S and
23S rRNA genes, and a 589-bp probe specific for
the blaOXA-23 gene. Labelling of the probes and
signal detection were carried out using a non-
radioactive labelling and detection kit, according
to the manufacturer’s instructions (GE Health-
care, Saclay, France). The endonuclease I CeuI
technique revealed a chromosomal location of
the blaOXA-23 gene in the four clonally related
isolates (isolates 1, 2, 4 and 5) with a hybrid-
ization signal obtained for a c. 40-kb band,
whereas the blaOXA-23 gene was located on a
70-kb plasmid in isolate 3 (data not shown). To
assess the plasmid location of blaOXA-23 in
isolate 3 more precisely, mating-out experiments
were performed with isolate 3 as donor and
A. baumannii BM 4547 as recipient strain, with
selection on ticarcillin (50 mg ⁄L) and rifampicin
(50 mg ⁄L), as previously described [12]. The
blaOXA-23-containing plasmid was transferred by
conjugation from A. baumannii 3 into A. bauman-
nii BM 4547. MICs for the blaOXA-23 transconju-
gants are indicated in Table 2.
In order to investigate the genetic structures
surrounding the blaOXA-23 gene, cloning
experiments were performed. Total DNA of
A. baumannii isolates was digested with the SacI
restriction enzyme, ligated into the SacI site of
plasmid pBK-CMV, and transferred by electro-
transformation into Escherichia coli TOP10, as
previously described [13]. Recombinant plasmids
were selected on Trypticase Soy agar plates
containing ticarcillin (50 mg ⁄L) and kanamycin
(30 mg ⁄L). Recombinant plasmid pAS1, obtained
from A. baumannii isolate 1, was sequenced on
both strands using an Applied Biosystems
sequencer (ABI 3100, Foster City, CA), which
allowed identification of the blaOXA-23 gene as
part of transposon Tn2006, as observed previ-
ously [14]. Analysis of nucleotide sequences at the
3¢-extremity of Tn2006 showed that its insertion
had occurred in the chromosome close to guaD, a
gene encoding a putative guanine deaminase
sharing 88% amino acid identity with that of
A. baumannii ATCC 17198 [15]. The 5¢-extremity
of Tn2006 was not available from recombinant
plasmid pAS1. Thus, primer 5¢-guanine (5¢-AT-
CGTACGGCATAAGTCTGC-3¢) was designed, on
the basis of the genome sequence of A. baumannii
ATCC 17198, and the remaining sequence of
guaD was successfully amplified. Sequencing of
the obtained PCR product revealed a duplication
of the target site composed of a 9-bp sequence
(AAGTTTTTG) at both Tn2006 ends, indicating
that the Tn2006 acquisition was likely to have
occurred through a transposition mechanism.
This structure was identified in A. baumannii
isolates 1, 2, 4 and 5. In isolate 3, ISAba1 was
detected upstream of the blaOXA-23 gene, but the
3¢-extremity of Tn2006 was not identified by PCR
mapping. Unfortunately, attempts to clone the
blaOXA-23 gene from isolate 3 remained unsuccess-
ful. Thus, it is likely that a different structure was
associated with the blaOXA-23 gene in the plasmid
in isolate 3.
This study provides the first description
of the dissemination of carbapenem-resistant
A. baumannii isolates carrying Tn2006 on their
chromosome. It is also the first report of OXA-23-
producing A. baumannii isolates in the Middle
East. It further emphasizes the major role of
CHDLs, and in particular of OXA-23, in the
emergence of carbapenem resistance in Acineto-
bacter spp.
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In vitro activity of tigecycline and
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A B S T R A C T
The in vitro activity of tigecycline was evaluated
against baseline pathogens isolated from patients
enrolled in phase 3 clinical trials for community-
acquired pneumonia conducted in 29 countries
worldwide. Tigecycline was active against the
most prevalent pathogens, including Streptococcus
pneumoniae (MIC90 0.06 mg ⁄L), Staphylococcus
aureus (MIC90 0.25 mg ⁄L), Haemophilus influenzae
(MIC90 0.5 mg ⁄L) and Klebsiella pneumoniae
(MIC90 1 mg ⁄L). Twelve isolates of S. pneumoniae
expressing tet(M) and two isolates of K. pneumo-
niae producing extended-spectrum b-lactamases
isolated during the study were susceptible to
tigecycline. The excellent in vitro activity of tige-
cycline against these clinical isolates confirmed its
potential utility against pathogens associated with
community-acquired pneumonia.
Keywords Community-acquired pneumonia, in vitro
susceptibility, respiratory isolates, tigecycline
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Tigecycline, the 9-t-butylglycylamido derivative
of minocycline, was developed by Wyeth in
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